Lexington, Mass., September 6, 2023 — KSQ Therapeutics, Inc. (“KSQ”), a clinical-stage biotechnology company developing cancer therapies using its proprietary CRISPRomics® discovery platform, and CTMC, a joint venture between National Resilience, Inc. and MD Anderson Cancer Center, announced today a strategic collaboration to expedite the development of KSQ’s two lead engineered tumor-infiltrating lymphocyte (eTIL® ) programs, KSQ-001EX and KSQ-004EX, both of which are advancing toward clinical studies for the treatment of solid tumors.
Download the full article: KSQ-CTMC-PR-9.6.23.pdf